Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Background: Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for patients with CRPC remains unclear. Objective: To evaluate whether ENZ or ABI is better as first-line treatment for CRPC. Design,...

Full description

Bibliographic Details
Main Authors: Kouji Izumi, Takashi Shima, Koji Mita, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono, Atsushi Mizokami
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:European Urology Open Science
Subjects:
Androgen deprivation therapy
Androgen receptor signaling–targeted therapy
Endocrine therapy
Castration-resistant prostate cancer
Enzalutamide
Abiraterone
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168322005912

Similar Items

Similar Items